Literature DB >> 8859179

Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma.

S Nakamura1, S Suzuki, T Sakaguchi, A Serizawa, H Konno, S Baba, S Baba, H Muro.   

Abstract

BACKGROUND: The results of treatment of mixed hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) remain unclear because of the rarity of this disease.
METHODS: Of 218 patients with primary liver carcinoma treated from 1979 to 1995, 6 had a histologic diagnosis of mixed HCC and CC (MHC). Five had chronic liver disease. Serum carcinoembryonic antigen (CEA), CA 19-9, and alpha-fetoprotein (AFP) levels were determined and hepatic angiography was performed preoperatively. Left trisegmentectomy (with portal vein reconstruction) and extended right lobectomy were performed in one patient each, whereas selective subsegmentectomy was done in three patients, and partial resection of segment 3 in one patient. Hilar lymphadenectomy was performed in two patients.
RESULTS: Mild liver dysfunction was observed in two patients. The resected tumors ranged from 2.7 to 12 cm in size and all showed intermingling of HCC and CC elements. A preoperative diagnosis of MHC was possible in one patient because of a high AFP level and hypovascularity, whereas a high CEA level and hypervascularity led to the diagnosis in another patient. High levels of AFP, CEA, and CA 19-9 were observed in three, one, and three patients, respectively. There were no metastases in the dissected lymph nodes. Although 2 patients had died by 2 years after surgery, the 5-year survival rate was 60% and there were 2 long term survivors for more than 10 years.
CONCLUSIONS: A hypervascular tumor with high CEA and CA 19-9 levels or a hypovascular tumor with a high AFP level may suggest a preoperative diagnosis of MHC in patients with suspected HCC. Extensive surgery is an effective treatment for this disease, except in patients with satellite nodules. Hilar lymphadenectomy may not be necessary in selected patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8859179     DOI: 10.1002/(sici)1097-0142(19961015)78:8<1671::aid-cncr6>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

Review 1.  Combined hepatocellular and cholangiocarcinoma associated with hepatolithiasis: report of a case.

Authors:  Kemal Deniz; Edip Torun; Mehmet Celikbilek; Erdoğan Sözüer
Journal:  Surg Today       Date:  2011-03-23       Impact factor: 2.549

Review 2.  Combined hepatocellular cholangiocarcinoma: a case report and review of literature.

Authors:  Shailender Singh; Subhankar Chakraborty; Neelima Bonthu; Stanley Radio; Shahid M Hussain; Aaron Sasson
Journal:  Dig Dis Sci       Date:  2013-02-09       Impact factor: 3.199

3.  A case of primary biliary cirrhosis that complicated with combined hepatocellular and cholangiocellular carcinoma.

Authors:  Masakazu Kobayashi; Kiyoshi Furuta; Hiroshi Kitamura; Kazuhiro Oguchi; Masayuki Arai; Shoichiro Koike; Koh Nakazawa
Journal:  Clin J Gastroenterol       Date:  2011-05-19

4.  High level of CA19-9, CA50, and CEA-producible human cholangiocarcinoma cell line changes in the secretion ratios in vitro or in vivo.

Authors:  M Watanabe; M Chigusa; H Takahashi; J Nakamura; H Tanaka; T Ohno
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-02       Impact factor: 2.416

5.  Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma.

Authors:  Di Tang; Hiroaki Nagano; Masato Nakamura; Hiroshi Wada; Shigeru Marubashi; Atsushi Miyamoto; Yutaka Takeda; Koji Umeshita; Keizo Dono; Morito Monden
Journal:  J Gastrointest Surg       Date:  2006 Jul-Aug       Impact factor: 3.452

6.  Markers of bile duct tumors.

Authors:  Giulia Malaguarnera; Maria Giordano; Isabella Paladina; Alessandra Rando; Mario Uccello; Francesco Basile; Antonio Biondi; Santo Carnazzo; Innocenza Alessandria; Clorinda Mazzarino
Journal:  World J Gastrointest Oncol       Date:  2011-04-15

7.  Primary hepatic cancers with multiple pathologic features in a patient with hepatitis C: report of a case.

Authors:  Go Oshima; Masahiro Shinoda; Minoru Tanabe; Yohei Masugi; Akihisa Ueno; Kiminori Takano; Minoru Kitago; Osamu Itano; Shigeyuki Kawachi; Kentaro Ohara; Masaya Oda; Akihiro Tanimoto; Michiie Sakamaoto; Yuko Kitagawa
Journal:  Int Surg       Date:  2012 Jan-Mar

8.  Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Xiao-Wen Huang; Yang Huang; Li-da Chen; Zhu Wang; Zheng Yang; Jin-Ya Liu; Xiao-Yan Xie; Ming-De Lu; Shun-Li Shen; Wei Wang
Journal:  J Med Ultrason (2001)       Date:  2017-10-20       Impact factor: 1.314

9.  Alpha-fetoprotein in canine multicentric lymphoma.

Authors:  R Lechowski; D Jagielski; M Hoffmann-Jagielska; M Zmudzka; A Winnicka
Journal:  Vet Res Commun       Date:  2002-06       Impact factor: 2.459

10.  Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer.

Authors:  T Uenishi; S Kubo; K Hirohashi; H Tanaka; T Shuto; T Yamamoto; S Nishiguchi
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.